Millendo Therapeutics Inc. (NASDAQ: MLND) is -76.11% lower on its value in year-to-date trading and has touched a low of $1.26 and a high of $12.73 in the current 52-week trading range. The MLND stock was last observed hovering at around $1.61 in the recent trading session, with the current gains setting it 0.06% off its average median price target of $5.00 for the next 12 months. It is also 66.6% off the consensus price target high of $5.00 offered by 3 analysts, but current levels are 44.33% higher than the price target low of $3.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
At last check, trading at $1.67, the stock is -20.80% and -16.00% below its SMA20 and SMA50 respectively. However, with a current trading volume of 0.63 million and changing 3.73% at the moment leaves the stock -69.93% off its SMA200. MLND registered -86.86% loss for a year compared to 6-month loss of -77.42%. The firm has a 50-day simple moving average (SMA 50) of $2.1254 and a 200-day simple moving average (SMA200) of $4.7492.
The stock witnessed a -27.80% gain in the last 1 month and extending the period to 3 months gives it a 11.03%, and is -10.06% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.66% over the week and 13.01% over the month.
Distance from 52-week low is 32.54% and -86.88% from its 52-week high.
Millendo Therapeutics Inc. (MLND) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Millendo Therapeutics Inc. (MLND) is a “Overweight”. 3 analysts offering their recommendations for the stock have an average rating of 1.70, where 1 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Millendo Therapeutics Inc. quarterly earnings per share for the current quarter are estimated at -$0.55.The EPS is expected to grow by 81.50% this year.
Millendo Therapeutics Inc. (MLND) Top Institutional Holders
92 institutions hold shares in Millendo Therapeutics Inc. (MLND), with 2.15M shares held by insiders accounting for 11.30% while institutional investors hold 73.81% of the company’s shares. The shares outstanding are 18.45M, and float is at 17.46M with Short Float at 4.32%. Institutions hold 65.47% of the Float.
The top institutional shareholder in the company is NEA Management Company, LLC with over 1.77 million shares valued at $9.33 million. The investor’s holdings represent 9.30% of the MLND Shares outstanding. As of Mar 30, 2020, the second largest holder is Great Point Partners LLC with 1.73 million shares valued at $9.13 million to account for 9.10% of the shares outstanding. The other top investors are Frazier Management LLC which holds 1.4 million shares representing 7.35% and valued at over $7.37 million, while Bpifrance SA holds 5.68% of the shares totaling 1.08 million with a market value of $5.7 million.
Millendo Therapeutics Inc. (MLND) Insider Activity
A total of 0 insider transactions have happened at Millendo Therapeutics Inc. (MLND) in the last six months, with sales accounting for 0 and purchases happening 0 times.